Discovery of novel tetrahydroquinoline derivatives as potent, selective, and orally Available AR antagonists
- 30 March 2025
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 291, 117566
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Zhejiang Province (2023C03110)
- Natural Science Foundation of Zhejiang Province (LD22H300001)
- National Natural Science Foundation of China (22377108)
- National Natural Science Foundation of China (U21A20301)
This publication has 16 references indexed in Scilit:
- Identification of Oral Bioavailable Coumarin Derivatives as Potential AR Antagonists Targeting Prostate CancerJournal of Medicinal Chemistry, 2024
- Discovery of Thiadiazoleamide Derivatives as Potent, Selective, and Orally Available Antagonists Disrupting Androgen Receptor HomodimerJournal of Medicinal Chemistry, 2024
- Therapeutic Strategies to Target the Androgen ReceptorJournal of Medicinal Chemistry, 2022
- A New Old Target: Androgen Receptor Signaling and Advanced Prostate CancerAnnual Review of Pharmacology and Toxicology, 2022
- Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluationEuropean Journal of Medicinal Chemistry, 2020
- A magic drug target: Androgen receptorMedicinal Research Reviews, 2018
- Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domainMedicinal Research Reviews, 2018
- Molecular Mechanisms of Enzalutamide Resistance in Prostate CancerCurrent Molecular Biology Reports, 2017
- Androgen receptor: structure, role in prostate cancer and drug discoveryActa Pharmacologica Sinica, 2014
- A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activitiesThe Prostate, 2011